EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Genomic, Trop‐2, and Immune Profiles of Carcinomatous and Sarcomatous Components in Ovarian Carcinosarcoma

Tomomi Sakamaki iD, Tatsuyuki Chiyoda iD, Kohei Nakamura iD, Reika Takamatsu, Ryutaro Kawano, Daisuke Ochiai iD, Mitsuyo Jisaka iD, Mio Takahashi iD, Takuma Yoshimura iD, Yumiko Kimura iD, Shinya Oki iD, Kensuke Sakai iD und 3 weitere

Cancer Reports · 2026

DOI: 10.1002/cnr2.70659 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Cancer Reports, 2026. Verfasst von Tomomi Sakamaki und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Antigens, Neoplasm, Biomarkers, Tumor, Carcinosarcoma, Cell Adhesion Molecules. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ovarian carcinosarcoma (OCS) is a rare, aggressive tumor composed of both carcinomatous and sarcomatous components, typically associated with poor prognosis. Due to its rarity, the molecular characteristics, immune microenvironment, and optimal treatment of OCS remain unclear. This study aimed to characterize the genomic profiles, Trop‐2 expression, and immune microenvironment of the carcinomatous and sarcomatous components of OCS separately, and to explore candidate therapeutic targets for this rare and aggressive tumor. Case This retrospective, single‐institution study analyzed nine cases of ovarian or fallopian tube carcinosarcoma treated between 2013 and 2023. Targeted next‐generation sequencing of 160 cancer‐related genes was performed in eight cases, and immunohistochemistry for p53, Trop‐2, CD8, and PD‐L1 was performed in nine cases, with the carcinomatous and sarcomatous components evaluated separately whenever they were separable. All tumors contained high‐grade serous carcinoma components. Targeted sequencing revealed TP53 mutations in all samples. Most genetic alterations were shared by both components, supporting the role of epithelial‐mesenchymal transition in OCS pathogenesis. Amplifications in CCND1 , CCNE1 , PRKCI , and GNAS (37.5%), and ERBB2 (12.5%) were detected, and whole genome duplication was observed in two cases (25%). One case (12.5%) showed high microsatellite instability and was associated with Lynch syndrome. Immunohistochemistry showed Trop‐2 positivity in all carcinomatous components, with a trend toward higher expression compared with sarcomatous areas ( p = 0.0625). CD8 and PD‐L1 levels were low, consistent with a relatively non‐inflamed, immune‐cold‐like microenvironment.

Conclusion

These findings suggest molecular similarities between OCS and high‐grade serous carcinoma and highlight the role of epithelial‐mesenchymal transition. The low immune marker expression suggests limited benefit from immune checkpoint inhibitors, except in select Lynch syndrome cases. In contrast, the consistently high Trop‐2 expression in the carcinomatous component may warrant further investigation of Trop‐2‐targeted antibody–drug conjugates as a hypothesis‐generating therapeutic candidate for OCS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, NeoplasmBiomarkers, TumorCarcinosarcomaCell Adhesion MoleculesOvarian NeoplasmsAgedFemaleHumansMiddle AgedMutationRetrospective StudiesTumor MicroenvironmentTumor Suppressor Protein p53Adult

Stichwörter der Autor:innen

CD8‐positive lymphocytescarcinosarcomaepithelial‐mesenchymal transitionovarian epithelial cancertumor immune evasion

Substanzen

Antigens, NeoplasmBiomarkers, TumorCell Adhesion MoleculesTACSTD2 protein, humanTumor Suppressor Protein p53

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.
  • Center for Cancer Genomics, Keio University School of Medicine, Tokyo, Japan.

ORCID-Profile: Tomomi Sakamaki, Tatsuyuki Chiyoda, Kohei Nakamura, Daisuke Ochiai, Mitsuyo Jisaka, Mio Takahashi, Takuma Yoshimura, Yumiko Kimura, Shinya Oki, Kensuke Sakai, Tomoko Yoshihama, Hiroshi Nishihara, Wataru Yamagami

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Sakamaki, T., Chiyoda, T., Nakamura, K., Takamatsu, R., Kawano, R., Ochiai, D., Jisaka, M., Takahashi, M., Yoshimura, T., Kimura, Y., Oki, S., Sakai, K., Yoshihama, T., Nishihara, H., & Yamagami, W. (2026). Genomic, Trop‐2, and Immune Profiles of Carcinomatous and Sarcomatous Components in Ovarian Carcinosarcoma. Cancer Reports. https://doi.org/10.1002/cnr2.70659

Vancouver

Sakamaki T, Chiyoda T, Nakamura K, Takamatsu R, Kawano R, Ochiai D, et al. Genomic, Trop‐2, and Immune Profiles of Carcinomatous and Sarcomatous Components in Ovarian Carcinosarcoma. Cancer Reports. 2026. doi:10.1002/cnr2.70659

BibTeX
@article{Sakamaki2026,
  author = {Sakamaki, Tomomi and Chiyoda, Tatsuyuki and Nakamura, Kohei and Takamatsu, Reika and Kawano, Ryutaro and Ochiai, Daisuke and Jisaka, Mitsuyo and Takahashi, Mio and Yoshimura, Takuma and Kimura, Yumiko and Oki, Shinya and Sakai, Kensuke and Yoshihama, Tomoko and Nishihara, Hiroshi and Yamagami, Wataru},
  title = {Genomic, Trop‐2, and Immune Profiles of Carcinomatous and Sarcomatous Components in Ovarian Carcinosarcoma},
  journal = {Cancer Reports},
  year = {2026},
  doi = {10.1002/cnr2.70659}
}
Kostenlos starten →